Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Phyllis, van der Ploeg"'
Autor:
Phyllis van der Ploeg, Cynthia SE. Hendrikse, Anna MJ. Thijs, Hans M. Westgeest, Huberdina PM. Smedts, M Caroline Vos, Mathilde Jalving, Christianne AR. Lok, Ingrid A. Boere, Maaike APC. van Ham, Petronella B. Ottevanger, Anneke M. Westermann, Constantijne H. Mom, Roy I. Lalisang, Sandrina Lambrechts, Ruud LM. Bekkers, Jurgen MJ. Piek
Publikováno v:
Heliyon, Vol 10, Iss 1, Pp e23170- (2024)
Objective: Ovarian cancer is the fifth cause of cancer-related death among women. The benefit of targeted therapy for ovarian cancer patients is limited even if treatment is stratified by molecular signature. There remains a high unmet need for alter
Externí odkaz:
https://doaj.org/article/ec80d08ac0c84967956ced20e2dd05ff
Autor:
Nienke van de Kruis, Phyllis van der Ploeg, Jody H.C. Wilting, M. Caroline Vos, Anna M.J. Thijs, Joanne de Hullu, Petronella B. Ottevanger, Christianne Lok, Jurgen M.J. Piek
Publikováno v:
Gynecologic Oncology Reports, Vol 42, Iss , Pp 101035- (2022)
Objective: Clinical efficacy of cytostatic anticancer agents can be determined with the progression-free survival (PFS) ratio. This outcome measure compares PFS achieved by a new treatment (PFS2) to the PFS of the most recent treatment on which the p
Externí odkaz:
https://doaj.org/article/81897c8e0e8b4228992aff841b0b5493
Autor:
Cynthia S. E. Hendrikse, Phyllis van der Ploeg, Nienke M. A. van de Kruis, Jody H. C. Wilting, Floor Oosterkamp, Pauline M. M. Theelen, Christianne A. R. Lok, Joanne A. de Hullu, Huberdina P. M. Smedts, M. Caroline Vos, Brenda M. Pijlman, Loes F. S. Kooreman, Johan Bulten, Marjolein H. F. M. Lentjes‐Beer, Steven L. Bosch, Anja van de Stolpe, Sandrina Lambrechts, Ruud L. M. Bekkers, Jurgen M. J. Piek
Publikováno v:
Cancer, 129(9), 1361-1371. Wiley
Cancer, 129, 9, pp. 1361-1371
Cancer, 129, 1361-1371
Cancer, 129, 9, pp. 1361-1371
Cancer, 129, 1361-1371
Contains fulltext : 291887.pdf (Publisher’s version ) (Open Access) BACKGROUND: Advanced low-grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4e78328b415fa76014a1b9e212d0c2b
https://cris.maastrichtuniversity.nl/en/publications/9e6e8598-eebd-4996-aa9c-7406328c4dbe
https://cris.maastrichtuniversity.nl/en/publications/9e6e8598-eebd-4996-aa9c-7406328c4dbe
Autor:
Phyllis, van der Ploeg, Aniek, Uittenboogaard, Steven L, Bosch, Paul J, van Diest, Yvonne J W, Wesseling-Rozendaal, Anja, van de Stolpe, Sandrina, Lambrechts, Ruud L M, Bekkers, Jurgen M J, Piek
Publikováno v:
Gynecologic Oncology, 165(1), 114-120. Elsevier Science
OBJECTIVE: To determine the activity of key signal transduction pathways in serous tubal intraepithelial carcinoma (STIC) and concurrent high-grade serous carcinoma (HGSC) and compare this to pathway activity in normal Fallopian tube epithelium (FTE)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb30700e131809290e17cccfd29f291d
https://doi.org/10.1016/j.ygyno.2022.01.027
https://doi.org/10.1016/j.ygyno.2022.01.027
Autor:
Ruud L.M. Bekkers, Phyllis van der Ploeg, Sandrina Lambrechts, Jurgen M.J. Piek, Hans M. Westgeest, Anna M.J. Thijs, Aniek Uittenboogaard, Anja van de Stolpe, Ingrid A. Boere
Publikováno v:
Gynecologic Oncology, 163(2), 433-444. Elsevier Science
Objective. To determine the clinical benefit of monotherapy with PI3K/AKT/mTOR inhibitors in patients diagnosed with advanced or recurrent ovarian cancer and to investigate the predictive value of current PI3K/AKT/ mTOR biomarkers on therapy response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1d4a86c00b11c2413b6be3b738bbee7
https://doi.org/10.1016/j.ygyno.2021.07.008
https://doi.org/10.1016/j.ygyno.2021.07.008
Autor:
Phyllis van der Ploeg, Cynthia Hendrikse, Anna Thijs, Hans M. Westgeest, Huberdina Smedts, Caroline Vos, Mathilde Jalving, C.A.R. Lok, Ingrid Boere, Maaike van Ham, Nelleke Ottevanger, Anneke M. Westermann, Constantijne Mom, Roy Lalisang, Sandrina Lambrechts, Ruud Bekkers, Jurgen M.J. Piek
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b25e4cd9661d105c9202a644f633997c
https://doi.org/10.2139/ssrn.4441215
https://doi.org/10.2139/ssrn.4441215
Autor:
Jurgen M.J. Piek, Phyllis van der Ploeg, Laura A.M. van Lieshout, Marjolein H.F.M. Lentjes-Beer, Ruud L.M. Bekkers, Steven L. Bosch, Anja van de Stolpe
Publikováno v:
Cellular Oncology (Dordrecht)
Cellular oncology, 44(4), 951-957. Springer
Cellular oncology, 44(4), 951-957. Springer
Purpose Anti-estrogen therapy may be used as a palliative treatment option in high-grade serous ovarian carcinomas (HGSC). However, clinical implementation is limited as the use of estrogen receptor (ER) protein expression by immunohistochemistry rem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::919ef7a72d3042eb309041416389ac0d
https://doi.org/10.1007/s13402-021-00600-5
https://doi.org/10.1007/s13402-021-00600-5
Autor:
Yvonne Wesseling-Rozendaal, Marjolein H.F.M. Lentjes-Beer, Jurgen M.J. Piek, Joanne A. de Hullu, Ruud L.M. Bekkers, Caroline Vos, Anja van de Stolpe, Steven L. Bosch, Laura A.M. van Lieshout, Meggy P.M. Ottenheijm, Leon F.A.G. Massuger, Phyllis van der Ploeg, Annelen Meriaan
Publikováno v:
Cancers
Volume 13
Issue 20
Cancers, 13(20):5101. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, Vol 13, Iss 5101, p 5101 (2021)
Cancers, 13
Cancers, 13, 20
Volume 13
Issue 20
Cancers, 13(20):5101. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, Vol 13, Iss 5101, p 5101 (2021)
Cancers, 13
Cancers, 13, 20
High-grade serous ovarian carcinoma (HGSC), the most common subtype of ovarian cancer, has a high mortality rate. Although there are some factors associated with survival, such as stage of disease, there are remarkable differences in survival among w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36624e788cfa97a02203274693515ee3
Autor:
Phyllis Van der Ploeg, Yvonne J.W. Wesseling-Rozendaal, Eveline C. Biezen-Timmermans, Jurgen M.J. Piek
Publikováno v:
Cancer Research. 82:4002-4002
Background: High-grade serous carcinoma (HGSC) is the most common subtype of ovarian cancer. It has a high mortality rate, even after successful first-line treatment with debulking surgery and chemotherapy. Although therapeutic options for targeted t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb8a8da8f88d6c97e699eb11f4f3d7a8
https://doi.org/10.1158/1538-7445.am2022-4002
https://doi.org/10.1158/1538-7445.am2022-4002
Autor:
Laura A.M. van Lieshout, Jurgen M.J. Piek, Anja van de Stolpe, David D.L. Bowtell, Joanne A. de Hullu, Phyllis van der Ploeg
Publikováno v:
Cancers
Cancers, 12, 9
Cancers, Vol 12, Iss 2660, p 2660 (2020)
Cancers, 12
Volume 12
Issue 9
Cancers, 12, 9
Cancers, Vol 12, Iss 2660, p 2660 (2020)
Cancers, 12
Volume 12
Issue 9
We investigated signal transduction pathway (STP) activity in high-grade serous ovarian carcinoma (HGSC) in relation to progression-free survival (PFS) and overall survival (OS). We made use of signal transduction pathway activity analysis (STA analy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::791f4337327b5c078d5e4f6ffe063d9e
https://pubmed.ncbi.nlm.nih.gov/32961868
https://pubmed.ncbi.nlm.nih.gov/32961868